You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

7 search results for: loss of smell

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

IRS-ISIAN 2024 | The Importance <b>of</b> Understanding <b>Smell</b> <b>Loss</b> and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

15 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

IRS-ISIAN 2024 | The Underappreciated Burden <b>of</b> <b>Smell</b> <b>Loss</b> and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

5 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

CRSwNP Significantly Affects the Quality <b>of</b> Life <b>of</b> CRSwNP Patients

interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

10 min

Rhinology

Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.

The Pathophysiology <b>of</b> Type 2 Inflammation in CRSwNP

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Defining Mechanisms <b>of</b> Anosmia in CRSwNP

videoanimation

Defining Mechanisms of Anosmia in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens examines what is known and what else should be explored to understand the mechanisms of anosmia in patients with CRSwNP.

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region